CA2002144A1 - Methode de prevention ou de reduction de l'eosinophilie - Google Patents

Methode de prevention ou de reduction de l'eosinophilie

Info

Publication number
CA2002144A1
CA2002144A1 CA2002144A CA2002144A CA2002144A1 CA 2002144 A1 CA2002144 A1 CA 2002144A1 CA 2002144 A CA2002144 A CA 2002144A CA 2002144 A CA2002144 A CA 2002144A CA 2002144 A1 CA2002144 A1 CA 2002144A1
Authority
CA
Canada
Prior art keywords
preventing
antagonist
reducing eosinophilia
human interleukin
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2002144A
Other languages
English (en)
Other versions
CA2002144C (fr
Inventor
Robert L. Coffman
Donna M. Rennick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23016493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2002144(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2002144A1 publication Critical patent/CA2002144A1/fr
Application granted granted Critical
Publication of CA2002144C publication Critical patent/CA2002144C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Optical Head (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pens And Brushes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Lubricants (AREA)
CA002002144A 1988-11-03 1989-11-02 Methode de prevention ou de reduction de l'eosinophilie Expired - Lifetime CA2002144C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26690988A 1988-11-03 1988-11-03
US266,909 1988-11-03

Publications (2)

Publication Number Publication Date
CA2002144A1 true CA2002144A1 (fr) 1990-05-03
CA2002144C CA2002144C (fr) 2000-03-28

Family

ID=23016493

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002002144A Expired - Lifetime CA2002144C (fr) 1988-11-03 1989-11-02 Methode de prevention ou de reduction de l'eosinophilie

Country Status (17)

Country Link
EP (2) EP0367596B1 (fr)
JP (1) JPH07563B2 (fr)
KR (1) KR960002183B1 (fr)
AT (1) ATE98872T1 (fr)
AU (1) AU633034B2 (fr)
CA (1) CA2002144C (fr)
DE (1) DE68911653T2 (fr)
DK (1) DK81691D0 (fr)
ES (1) ES2062032T3 (fr)
HK (1) HK186196A (fr)
IE (1) IE63063B1 (fr)
IL (1) IL92180A (fr)
MY (1) MY107386A (fr)
NZ (1) NZ243939A (fr)
PH (1) PH26476A (fr)
WO (1) WO1990004979A2 (fr)
ZA (1) ZA898322B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49597A1 (en) * 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
CA2155109A1 (fr) * 1993-02-01 1994-08-18 Daniel Abramowicz Utilisation d'une composition pharmaceutique renfermant une quantite efficace d'interleukine-10, un analogue et (ou) un agoniste d'interleukine-10
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP2001523083A (ja) * 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
KR20100134702A (ko) 2008-03-28 2010-12-23 글락소스미스클라인 엘엘씨 치료 방법
CN110913887A (zh) 2017-06-06 2020-03-24 葛兰素史克有限责任公司 用于儿科患者的生物药物组合物和方法
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512796B2 (ja) * 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法

Also Published As

Publication number Publication date
WO1990004979A2 (fr) 1990-05-17
EP0367596B1 (fr) 1993-12-22
NZ243939A (en) 1997-07-27
DK81691A (da) 1991-05-02
HK186196A (en) 1996-10-11
CA2002144C (fr) 2000-03-28
PH26476A (en) 1992-07-27
ZA898322B (en) 1990-11-28
DE68911653D1 (de) 1994-02-10
KR960002183B1 (ko) 1996-02-13
IL92180A (en) 1997-04-15
IL92180A0 (en) 1990-07-26
JPH03505211A (ja) 1991-11-14
ES2062032T3 (es) 1994-12-16
IE893525L (en) 1990-05-03
WO1990004979A8 (fr) 2005-06-16
AU633034B2 (en) 1993-01-21
IE63063B1 (en) 1995-03-22
ATE98872T1 (de) 1994-01-15
EP0441891A1 (fr) 1991-08-21
DE68911653T2 (de) 1994-04-07
DK81691D0 (da) 1991-05-02
JPH07563B2 (ja) 1995-01-11
EP0367596A1 (fr) 1990-05-09
MY107386A (en) 1995-11-30
AU4644889A (en) 1990-05-28
KR900701320A (ko) 1990-12-01

Similar Documents

Publication Publication Date Title
AU3038389A (en) Method of reducing immunoglobulin e responses
EP0597829A4 (fr) Nouvel anticorps monoclonal dresse contre un nouvel antigene associe aux tumeurs humaines.
AU4688589A (en) A method for treatment of endotoxic shock in a mammal
EP0409607A3 (en) Antibody to human interleukin-6 receptor
GB2185266B (en) Monoclonal antibodies cross-reactive and cross-protective against p. aeruginosa serotypes
EP0312996A3 (en) Anti-human bcdf monoclonal antibody
AU4644889A (en) Method of preventing or reducing eosinophilia
EP0216454A3 (en) Method of promoting animal growth
EP0341684A3 (en) Human monoclonal antibody, hybridoma producing the same and pharmaceutical
WO1991007986A8 (fr) Methode de traitement de choc septique
AU3088984A (en) Antibodies and compositions thereof for inhibiting dental induced by s. abitans
AU2546088A (en) Human monoclonal antibody against aspergilli
ZA868673B (en) Monoclonal antibodies cross-reactive and cross-protective against p.aeruginosa serotypes
ZA912138B (en) Bcrf1 antagonists for treating epstein-barr virus infections
AU3413189A (en) Therapeutic murine monoclonal antibody
CS792587A1 (en) Mouse lymphocytaric hybridom producing antibody against human alpha-fetoproteine
CS339888A1 (en) Mouse lymphocytaric hybridom nf-01 producing antibody against 210 kda protein neurofilament
CS495286A1 (en) Mouse lymhocytaric hybridom producing antibody against human choriogonadotropic hormone
CS8905415A1 (en) Murine lymphocyte hybridoma img-czas he-195 producing antibody against human group antigen a
CS101189A1 (en) Img-czas afp-15 murine lymphocyte hybridoma producing antibody against human alpha-foetoprotein

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry